Latest news with #WoltersKluwerHealth
Business Wire
16-07-2025
- Business
- Business Wire
Royal Devon NHS selects Wolters Kluwer's UpToDate Enterprise Edition CDS solution
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health announced today that the Royal Devon University Healthcare NHS Foundation Trust, an organization providing acute, community and specialist services across North Devon, Mid Devon, East Devon and Exeter, is the first NHS Trust to adopt UpToDate ® Enterprise Edition, a market-leading clinical decision support (CDS) solution. The Trust includes two acute hospitals and 17 community hospitals with over 1,100 beds. 'Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,' said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. 'By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision-making, helping us to deliver the best possible care for all patients, and enabling our local population to stay well.' UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. Using its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities. 'We are pleased to be working with The Royal Devon University Healthcare NHS Foundation Trust on the roll out of UpToDate Enterprise Edition,' said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. 'This is an innovative solution designed for forward thinking healthcare systems that are focused on transforming care delivery through integrated workflows that provide unparalleled content and faster time to answers.' Delivering high quality, efficient healthcare services 'Providing access to an evidence-based CDS like UpToDate helps reduce variability in care, drive better patient outcomes and save clinician time through faster decision-making at the point-of-care,' Prof. Harris continued. 'Diagnosing quickly and treating appropriately with the help of CDS means better care, better patient outcomes, and better use of invaluable healthcare resources.' Over 100 independent studies of UpToDate associate the use of the resource with clinician time savings and improvements on key hospital quality and efficiency metrics such as length of stay, medical errors, and unnecessary diagnostic testing. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Newsweek
26-06-2025
- Health
- Newsweek
Joint Commission CEO Breaks Down New AI Certification
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox. I've settled on my word of the week: transparency. Over the last seven days, my schedule has looked like a patchwork quilt, spanning several distinct sectors of the health care industry. But from the government's roundtable on prior authorization reform to my conversation with Joint Commission CEO Dr. Jonathan Perlin (read on for more on both of those), transparency has emerged as a common thread. Health systems and insurance companies must be transparent with one another; health systems and insurance companies must be transparent with patients. And, of course, health care companies must be transparent with their employees and customers—especially when deploying AI. Monday through Wednesday, many of my colleagues were in sunny Sonoma, California, for Newsweek's cross-industry AI Impact Summit. Senior Reporters Lauren Giella and Katherine Fung kept eyes on the health care side of the agenda, which included speakers from Kaiser Permanente, Hospital for Special Surgery, AdventHealth and UMass Medical. "Transparency was a big theme for AI adoption in health care—not only when dealing with medical records and personal data, but also for why and how organizations are implementing automation tools," Giella wrote. Dr. Allen Chang, ACMIO at UMass Medical, warned the audience not to neglect employees' concerns about losing jobs to AI, nodding to last year's strike by the California Nurses Association. "A lot of us say that we're not going to be replaced by AI, we want to believe that, but in medicine, we can't just invoke this and expect that to address the underlying drivers as to why people are asking about this," Chang said on Tuesday's health care panel. What could those underlying drivers be? I found some clues in Wolters Kluwer Health's new generative AI readiness report, released at the start of the month. Their survey of health care stakeholders found that 76 percent cite "reducing clinician burnout" as a major priority, and 85 percent say "recruiting/retaining nursing staff" is top of mind. But only 45 percent of nurses responded "yes" when asked if generative AI can reduce clinician burnout. I asked Dr. Peter Bonis, chief medical officer at Wolters Kluwer Health, to help me make sense of that gap—or "disconnect," as he called it. "Our survey is indicating that there's an opportunity to work with allied health professionals and clinicians to deeply understand their needs and where some of these technologies can help; to have them on participatory boards as they themselves get educated on what these tools can do; and to select these tools so that they are optimizing their workflows, and they have agency in this process," he said. I've been reporting on a lot of AI-related "disconnects" lately, both within health systems' AI deployment efforts and in external communications with vendors. I asked Bonis: Do these lapses indicate that we're taking the wrong approach to AI deployment in the health care industry? He told me that this isn't exclusive to the health care industry, and that every business is wrestling with the same sort of issues. (Phew.) But, he acknowledged, health care is a high-stakes game, and it's important to deploy AI safely (and transparently) for the benefit of employees, patient care and overall health equity. He believes health systems will succeed if they focus on patient care and bolster that foundation with sound operations and a successful business model. "The fusion of those two directives is what creates a future-ready health care system that understands how to use these advanced technologies to advance their operations—to do that thoughtfully—and then to have a coherent pathway to start to use these tools to advance that higher stakes domain," Bonis said, "and that's the journey that we're on." I also spoke with Dr. Perlin, head of the Joint Commission, about that journey to a "coherent" AI pathway. Read on to the Pulse Check section to see what he said. Essential Reading Aiming to improve the prior authorization process, HHS Secretary Robert F. Kennedy, Jr., and CMS Administrator Dr. Mehmet Oz hosted a roundtable of health insurance executives and stakeholders on Monday. on Monday. Attendees agreed to six reforms: (1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials. (1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials. These companies were included in the discussion: Aetna, AHIP, Blue Cross Blue Shield Association, CareFirst BlueCross BlueShield, Centene Corporation, The Cigna Group, Elevance Health, GuideWell, Highmark Health, Humana, Kaiser Permanente and UnitedHealthcare. Together, they represent about 75 percent of Americans with commercial or Medicare Advantage plans. The Lown Institute has released its highly anticipated index of America's Most Socially Responsible Hospitals. This year's honor roll comes at a critical time, as hospitals work to maintain equitable care amid potential Medicaid cuts, rising costs and ongoing workforce challenges. Duke Regional Hospital topped this year's acute care ranking, marking its fifth year on the list. Eli Lilly's once-weekly insulin efsitora displayed promising results in Phase 3 clinical trials, reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections. Diabetes is becoming more prevalent in the United States , affecting nearly 15 percent of adults. By the end of 2025, Eli Lilly plans to submit the drug to global regulatory agencies for the treatment of Type 2 diabetes. reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections. Artisight, the NVIDIA-backed health tech company specializing in AI-powered "smart hospital" infrastructure, announced a $40 million investment from a dozen health systems. It's an unprecedented level of support from some of the nation's largest, most forefront integrated systems and academic medical centers. (The list of names was reviewed by Newsweek but is not being released to the public at this time.) Pulse Check Dr. Jonathan Perlin is president and CEO of the Joint Commission. Dr. Jonathan Perlin is president and CEO of the Joint Commission. Joint Commission If you've been paying attention to the news lately, you may have had the same question that I did: What on earth is going on at the Joint Commission?The independent health care accreditation and certification organization has launched a couple high-profile, high-tech partnerships in recent weeks. First, it announced a long-term relationship with Palantir, intending to use the company's AI platform to streamline accreditation/certification processes. Then, it joined forces with the Coalition for Health AI to establish a "suite" of AI best practices playbooks and a new certification for hospitals. Now, if you work at a hospital, you likely live by the Joint Commission's standards. That's why I called Dr. Jonathan Perlin, president and CEO of The Joint Commission, last Friday. There was a bit of "geeking out about AI," as Perlin put it. But mostly, we discussed the recent CHAI partnership—and what it could mean for quality/safety standards and hospital certifications. Editor's Note: Responses are lightly edited for length and clarity. AI is so different from other components used to assess quality. Each health system uses it in a unique way, and applications vary between hospitals, departments and even patient populations. "Good AI" can be tough to quantify. How do you plan to create a standard with this new certification program? CHAI's lane is really the technology itself, and ours is the organization's governance process for the responsible use of that. You may have seen our Responsible Use of Health Data Certification that has six attributes, and this is really an extension of that. What we anticipate—and this is a work in progress—is that building from the Responsible Use of Health Data [Certification], there'd be requirements for de-identification or privacy that could be data controls for security. There should be some mechanism for transparency with patients. Most importantly, there would be like an oversight or governance structure that addresses the algorithm's or the AI's performance. The notion is that an organization can look to CHAI and to the market to identify an AI tool, but it has to have an active and ongoing governance process to look at the performance of that tool in their environment. To give an example, I think there are three essential components. One is technical: Is [the tool] valid and reliable in a sort of mathematical sense? Second, is it valid and reliable clinically? Does it present the right clinical information? And third, is it valid and reliable in a demographic sense, that you're not applying an AI trained specifically for detection of sepsis in adults to children. To make that clear, if CHAI's lane is really the external performance of the algorithm and the assurance aspects outside of health care, the way we do this [new certification] is not specifically directed at the certification of the AI tool, but the certification of process for the organization's own governance and oversight of the use responsible use of that AI tool. Will this certification assess tools that health systems developed internally, vendor tools that they deploy, or a combination of both? What else will you be looking at within each hospital's AI ecosystem? We anticipate that the certification, which would be given to health care organizations, would be based on the governance structure and the oversight structure I described [above]. We expect it would be applied both to homegrown and off-the-shelf technologies. Our focus is on continuous governance. Let me give an example that's literally closer to home. We just finished a renovation [at my house], and we had an electrical inspection after the work was completed. The wiring of the house is not going to change over time, but the wiring of AI, if it's retrained, if it drifts, etc., may change over time—so the organization needs to have a mechanism for periodic review of the performance of its "electrical system," to use the analogy, not just at inception, but periodically, or frankly, for the life of the use of that technology. Any advice for health systems that are currently building up their AI governance structures, to ensure they're on the right path ahead of the Joint Commission and CHAI's certification? Take a look at our Responsible Use of Health Data Certification , because it really provides insight into the concepts of governance as the regulatory frameworks are emerging. Despite the fact that device drug approvals are static, they are viewing the use of device (good outcomes or bad) as the responsibility of the clinicians and health care organizations that use those. Having come from operations and large systems myself, it's really important to have a set of externally validated standards that demonstrate what "good" looks like for responsible governance and oversight. I think organizations like ours are hugely excited about the potential, but we want to set up common standards to assure that we realize that potential responsibly. If you liked this sneak peek, remember to check out next week's edition, which will include more of my interview with Perlin. C-Suite Shuffles Joseph Impicciche is retiring as CEO of Ascension, after six years at the helm of the St. Louis-based system. Eduardo Conrado, the health system's current president, will become its new CEO on January 1, 2026. Conrado was named to Ascension's executive team in 2018, after five years on its board of directors. Throughout his tenure, he has also served as the system's chief digital officer and chief strategy and innovation officer. The Medical University of South Carolina (MUSC) has selected Dr. John Marymont as its next provost and executive vice president for academic affairs. Currently, he serves as vice president for medical affairs and dean of the medical college at the University of South Alabama. Lovelace Health System is undergoing its fourth CEO change since 2022, the Albuquerque Journal reported. President and CEO Troy Greer resigned last week after two years in the role. The health system—one of the largest in New Mexico—declined to comment on his exit. Executive Edge Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals. Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals. Dr. Leigh Vinocur Dr. Leigh Vinocur tells me that she considers herself a "lifelong learner." She's spent her career learning different elements of medicine, starting as a urology resident, becoming a board-certified emergency physician and serving as chief medical director for a major health system, overseeing more than 100 providers in the mid-Atlantic region. Now, she is the medical director of a men's health clinic and works part-time in clinical trials at a nutraceutical company. But throughout her working life, Vinocur has also learned a great deal about stress. After leaving her big-box health care role, she dealt with a "corporate medicine hangover." On July 12, she's releasing a book about her journey: Never Let Them See You Sweat: How Science Can Help Us Harness Stress for Success. This week, I connected with Vinocur to learn what her research—and personal experiences—taught her about stress in the health care setting. Here's what she told me: Editor's Note: Responses are lightly edited for length and clarity. "Today, in this political climate, we're seeing changes to health care, erosion of public health. It's making it even more difficult [to work in health care leadership]. There were always issues as a physician, fighting with insurance companies—but as physician executives, it's that kind of double bind that they're in, because they're caregivers, but they're administrators. They have rules they're enforcing, fiscal and institutional constraints, but they have to put their patients first, too. And it's stressful. "Not all stress is always horrible and bad. It gets you to your tiptop performance, you know. Stress was an evolutionary development and advantage to keep us safe. If you were out there being chased by a predator, all those reactions from the hypothalamus, the pituitary, the adrenal release the cascade of hormones for that fight or flight. Whether you're a runner in the Olympics standing in the blocks, or whether you're an ER doctor waiting in the resuscitation room for those accident victims to come in, that little boost of stress gets you at your top performance. It's just this continued stress that is so challenging. "I tell executive leaders that they need some buffer in between meetings. You need to create little micro-breaks during the day that are just for you to calm down. Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing). Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing). "All throughout the book, there are discussions on things you can do in nature, like 'forest bathing.' Study after study says that if you can get to a green space, like a park, that can lower your blood pressure. Just being out in nature, getting outside—you don't even have to exercise—can be a great relief." This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Business Wire
09-06-2025
- Business
- Business Wire
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care. 'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.' Sentri7 Drug Diversion delivers improved workflows The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like: User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up. Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern. Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions. 'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025. Sentri7 Pharmacy updates support patient-centered care The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include: User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population. Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics. Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes. When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.' Learn more about the enhanced Sentri7 solutions. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Business Wire
04-06-2025
- Business
- Business Wire
Wolters Kluwer Again Recognized as Clinical Decision Support Leader
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health has once again been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS). Evaluating over 60 companies, the Frost Radar spotlights 10; Wolters Kluwer was the only one named both a 'Company to Action' and the market leader for innovation. The company was also a leader in the 2023 report. Wolters Kluwer Health has been identified as one of the top two companies in the new Frost Radar™ report on Clinical Decision Support Systems (CDSS) and the only one named both a 'Company to Action' and the market leader for innovation. Share According to the Frost report, the top-right Radar position of Wolters Kluwer shows it 'has firmly established itself as a leader in the CDSS market, with impressive R&D investment, and recent and upcoming product launches. The company's strategic integration of emerging technologies, particularly Gen AI, has positioned it at the forefront of next-generation CDSS solutions.' The report also recognizes the company's redefinition of the CDSS category with its introduction of UpToDate Enterprise Edition stating it 'is designed to align buyers, administrators, and care teams on a singular platform. This strategic alignment is key in enhancing care delivery and realizing superior returns on investment. With advanced on-demand analytics, this edition offers system-level insights into product usage, community trends, education needs, and the overarching impact of UpToDate on healthcare systems.' 'The Frost Radar is a deep dive into the CDSS market and its vendors. Based on our analysis, Wolters Kluwer has achieved significant growth for its solutions by focusing on innovation and customer-centric solutions,' said Dr. Rishi Pathak, Global Director of Healthcare & Life Sciences, Frost & Sullivan. 'That, combined with their strategy to increase the reach of UpToDate through integration into the clinician workflow and the intention to address adjacent operational and financial workflows, puts them in the leadership position.' Wolters Kluwer Health recently announced the integration of UpToDate with several ambient AI leaders, including Abridge, Suki, Microsoft and others. 'Being named the innovation leader in the Frost Radar reinforces our focus on innovation and interconnectivity and validates our commitment to transforming healthcare through product innovation and strategic partnerships,' said Greg Samios, CEO of Wolters Kluwer Health. 'We remain dedicated to helping providers make faster, smarter decisions across the care continuum, while enabling organizations to maximize their UpToDate investment through insightful analytics, harmonized content, seamless integration, and AI-enhanced features.' Learn more about Wolters Kluwer in the Frost Radar on CDSS. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Business Wire
03-06-2025
- Business
- Business Wire
Wolters Kluwer Future Ready Healthcare Survey Report Reveals Significant Opportunity for Healthcare GenAI—If Health Systems Can Overcome the Readiness Gap
WALTHAM, Mass.--(BUSINESS WIRE)--The new 2025 Future Ready Healthcare Survey Report from Wolters Kluwer Health, conducted in partnership with the independent marketing research firm Ipsos, reveals that while healthcare professionals widely recognize the transformative potential of generative AI (GenAI), most organizations are not yet ready to harness its full value. Wolters Kluwer Health/Ipsos survey reveals most healthcare organizations are not yet ready to harness the full value of GenAI, despite interest among professionals. Share The survey identifies strong enthusiasm for using GenAI to address the current challenges of workforce shortages, burnout, high healthcare costs, and rising administrative burdens, as well as keen interest in leveraging GenAI to achieve the next level of innovation and efficiency across the enterprise. However, the data also shows a clear disconnect between what organizations say they want to achieve with GenAI and how prepared they are to deliver on that promise. For example, while 80% of respondents cited 'optimizing workflows' as a top organizational goal, only 63% feel prepared to use GenAI to do so. 'GenAI has the potential to be a powerful tool for supporting sustainability in healthcare organizations right now, as well as preparing them for a more efficient future,' said Greg Samios, CEO of Wolters Kluwer Health. 'The challenge is developing a strategy that can both optimize the current state in a highly volatile environment and simultaneously equip organizations with the digital capabilities they need to remain competitive over the next several years. Right now, organizations are at risk of falling behind unless they take a more cohesive approach to making GenAI standardized, scalable, and impactful.' Key Findings: Nurse staffing and workforce concerns are at the top of the priority list for health GenAI applications: 85% of respondents cited 'recruiting/retaining nursing staff' as a top priority, while 76% identified 'reducing clinician burnout' as a main concern. Leaders are focusing on the basics to keep the enterprise running: GenAI-driven technologies are likely to be part of the solution for longstanding challenges, such as addressing the burdens of prior authorizations (67%), electronic health record (EHR) management (62%), cybersecurity preparedness (68%), and supporting telehealth/virtual care programs (65%). But clinical staff expect more from the GenAI revolution: In qualitative responses, participants said they understand and acknowledge the need for workflow optimization but also want to see innovative capabilities such as ambient listening, clinical decision support leveraging GenAI, and assistance with communication and documentation utilizing GenAI. Formal GenAI policies and guidance are scarce: Only 18% of respondents were aware of formal organizational policies governing GenAI use, and only 1 in 5 reported being required to take structured training. As a result, concerns about appropriate implementation persist: More than half (57%) believe that overreliance on GenAI may erode clinical decision-making skills, while 55% are concerned that lack of transparency around GenAI's potential role in making diagnoses could contribute to unclear reasoning behind patient-facing decisions. 'To successfully integrate GenAI, organizations must recognize its current limitations, as well as anticipate its realistic evolution and the regulatory landscape,' said Dr. Peter Bonis, Chief Medical Officer, Wolters Kluwer Health. 'It is also vital to select GenAI applications that align with both clinical and financial goals while fitting into existing workflows. Establishing robust and ongoing governance will be essential to succeed.' About the Wolters Kluwer 2025 Future Ready Healthcare Survey Report The 2025 Future Ready Healthcare Survey Report is based on a nationally representative survey conducted by Ipsos, an independent marketing research firm, in early 2025. Respondents included physicians, nurses, pharmacists, allied health professionals, administrators, and medical librarians across the US. Download the 2025 Future Ready Healthcare Survey Report to read more. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
